Allogene Therapeutics Statistics
Share Statistics
Allogene Therapeutics has 218.73M
shares outstanding. The number of shares has increased by 4.06%
in one year.
| Shares Outstanding | 218.73M |
| Shares Change (YoY) | 4.06% |
| Shares Change (QoQ) | 3.62% |
| Owned by Institutions (%) | 90.07% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 18,754 |
| FTD / Avg. Volume | 0.53% |
Short Selling Information
The latest short interest is 30.13M, so 13.87% of the outstanding
shares have been sold short.
| Short Interest | 30.13M |
| Short % of Shares Out | 13.87% |
| Short % of Float | 19.22% |
| Short Ratio (days to cover) | 13.41 |
Valuation Ratios
The PE ratio is -1.61 and the forward
PE ratio is -1.15.
Allogene Therapeutics's PEG ratio is
0.04.
| PE Ratio | -1.61 |
| Forward PE | -1.15 |
| PS Ratio | 18861.32 |
| Forward PS | 0.6 |
| PB Ratio | 0.98 |
| P/FCF Ratio | -2.06 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Allogene Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.54,
with a Debt / Equity ratio of 0.21.
| Current Ratio | 8.54 |
| Quick Ratio | 8.54 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | -0.37 |
| Debt / FCF | -0.45 |
| Interest Coverage | -1509.39 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $97.35 |
| Profits Per Employee | $-1,139,778.76 |
| Employee Count | 226 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 443K |
| Effective Tax Rate | -0.17% |
Stock Price Statistics
The stock price has increased by -58.27% in the
last 52 weeks. The beta is 0.6, so Allogene Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.6 |
| 52-Week Price Change | -58.27% |
| 50-Day Moving Average | 1.47 |
| 200-Day Moving Average | 2.13 |
| Relative Strength Index (RSI) | 38.24 |
| Average Volume (20 Days) | 3,566,403 |
Income Statement
In the last 12 months, Allogene Therapeutics had revenue of 22K
and earned -257.59M
in profits. Earnings per share was -1.32.
| Revenue | 22K |
| Gross Profit | 22K |
| Operating Income | -273.2M |
| Net Income | -257.59M |
| EBITDA | -243.33M |
| EBIT | -256.97M |
| Earnings Per Share (EPS) | -1.32 |
Full Income StatementBalance Sheet
The company has 75.22M in cash and 90.76M in
debt, giving a net cash position of -15.54M.
| Cash & Cash Equivalents | 75.22M |
| Total Debt | 90.76M |
| Net Cash | -15.54M |
| Retained Earnings | -1.82B |
| Total Assets | 507.98M |
| Working Capital | 261.55M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -200.3M
and capital expenditures -694K, giving a free cash flow of -200.99M.
| Operating Cash Flow | -200.3M |
| Capital Expenditures | -694K |
| Free Cash Flow | -200.99M |
| FCF Per Share | -1.03 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -1241813.64% and -1170863.64%.
| Gross Margin | 100% |
| Operating Margin | -1241813.64% |
| Pretax Margin | -1168850% |
| Profit Margin | -1170863.64% |
| EBITDA Margin | -1106031.82% |
| EBIT Margin | -1241813.64% |
| FCF Margin | -913609.09% |
